Understanding and innovating in cell therapy quality control: an interview with Stephen Sullivan, GAiT

Written by RegMedNet

Stephen Sullivan (GAiT) reflects on the evolution of quality control in the field of cell therapy, and discusses what the future may hold and what obstacles still remain. How have quality control needs changed since you began working in this field? Derivation of human induced pluripotent stem cells (iPSCs) was first described by Prof Yamanaka and members of his laboratory in 2007 and, given these reprogrammed cells capacity to self-renewal or produce differentiated progeny, their clinical potential for cell replacement therapy was manifest since that discovery. However, it is only recently institutions around the world have begun to entertain the practical challenges...

To view the full article, please register now for access

It's completely free